XML 23 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jul. 01, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 627,000 $ 647,169
Short-term investments 907,938 819,905
Trade receivables, net 235,400 282,650
Inventory 33,020 27,493
Prepaid expenses and other current assets 48,281 57,530
Total current assets 1,851,639 1,834,747
Long-term investments 463,889 371,112
Property and equipment, net 108,529 104,031
Deferred tax assets, net 113,958 111,663
Goodwill 63,684 63,684
Other long-term assets 279,705 131,002
Total assets 2,881,404 2,616,239
Current liabilities:    
Accounts payable 19,978 24,258
Accrued compensation and benefits 61,450 61,969
Accrued clinical trial liabilities 76,740 77,544
Rebates and fees due to customers 43,795 33,700
Accrued collaboration liabilities 29,990 86,753
Other current liabilities 72,568 53,366
Total current liabilities 304,521 337,590
Long-term portion of deferred revenues 7,209 8,739
Long-term portion of operating lease liabilities 161,019 51,272
Other long-term liabilities 17,395 8,023
Total liabilities 490,144 405,624
Commitments and contingencies
Stockholders' equity    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 321,800 and 318,842 at June 30, 2022, and December 31, 2021, respectively 322 319
Additional paid-in capital 2,477,117 2,427,561
Accumulated other comprehensive loss (8,917) (758)
Accumulated deficit (77,262) (216,507)
Total stockholders' equity 2,391,260 2,210,615
Total liabilities and stockholders' equity $ 2,881,404 $ 2,616,239